BMO Capital Markets Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX) had its price target boosted by BMO Capital Markets from $130.00 to $143.00 in a research report report published on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.

Other analysts also recently issued research reports about the company. Truist Financial assumed coverage on BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 target price for the company. Wells Fargo & Company assumed coverage on BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective for the company. JPMorgan Chase & Co. lowered their price objective on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research report on Tuesday, November 26th. Canaccord Genuity Group boosted their price objective on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research report on Wednesday, November 27th. Finally, Berenberg Bank assumed coverage on BioNTech in a research report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $143.73.

BioNTech Stock Performance

NASDAQ:BNTX opened at $97.46 on Tuesday. The business has a 50 day moving average of $116.18 and a 200 day moving average of $113.04. The company has a market capitalization of $23.37 billion, a price-to-earnings ratio of -46.41 and a beta of 0.30. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 EPS. On average, sell-side analysts predict that BioNTech will post -3.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently made changes to their positions in the business. Fred Alger Management LLC bought a new position in shares of BioNTech during the third quarter valued at approximately $59,485,000. Baillie Gifford & Co. grew its stake in BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after purchasing an additional 31,773 shares during the period. Charles Schwab Investment Management Inc. grew its stake in BioNTech by 123.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock worth $15,919,000 after purchasing an additional 74,119 shares during the period. SG Americas Securities LLC grew its stake in BioNTech by 412.3% in the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock worth $4,726,000 after purchasing an additional 33,375 shares during the period. Finally, Mirabaud & Cie SA purchased a new stake in BioNTech in the fourth quarter worth $684,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.